Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

NCT03319849 is registered in ClinicalTrials.gov with Neurotech Pharmaceuticals as lead sponsor.

NCT NCT03319849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03319849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2
Lead sponsor
Neurotech Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
January 22, 2018
Completion date
September 23, 2022
Enrollment
119 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

macular telangiectasia type 2